ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial. This double-blind study evaluated two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of patients with pseudobulbar affect (PBA) secondary to ALS or multiple sclerosis (MS). In the ALS patient subset, both Zenvia 30/10 mg and Zenvia 20/10 mg met the primary efficacy endpoint by significantly reducing daily PBA episode rates compared to placebo (p<0.0001 for both treatment groups). These results were presented today during a podium presentation at the 20th International Symposium on ALS/MND in Berlin, Germany.
